Predictive value of the Elixhauser comorbidity index in assessing the risk of coronavirus disease (COVID-19) mortality in patients with pneumonia
DOI:
https://doi.org/10.14739/2310-1210.2025.1.317977Keywords:
coronavirus disease, COVID-19, viral infection, pneumonia, comorbidity, Elixhauser comorbidity index, diagnosis, prognosisAbstract
Aim. To determine the spectrum of comorbid pathology and to find out the prognostic value of the Elixhauser Comorbidity Index (ECI) in assessing the risk of death from coronavirus disease (COVID-19) in patients with pneumonia.
Material and methods. The study included 123 patients with COVID-19 with pneumonia who were examined and treated according to the Order of the Ministry of Health of Ukraine of 28.03.2020 No. 722. Depending on the disease outcome, the patients were divided into groups: 77 patients who recovered and 46 patients who died. The ECI was calculated for all the patients. Statistical processing of the data was performed using Statistica for Windows 13 (StatSoft Inc., No. JPZ804I382130ARCN10-J).
Results. In patients with COVID-19 and pneumonia, comorbid conditions were most often represented by chronic cardiovascular disease (63.4 %), obesity (28.5 %), endocrine pathology (26.0 %) and discirculatory encephalopathy (23.6 %). Among patients with a fatal outcome, coronary heart disease with cardiac arrhythmias, obesity, endocrine diseases, primarily diabetes mellitus, and discirculatory encephalopathy were more common (p < 0.05) as compared to patients who recovered. Among the comorbidities integrated into the ECI, the most commonly diagnosed comorbidities in COVID-19 patients with pneumonia were hypertension (58.5 %), congestive heart failure (33.3 %), obesity (28.5 %), neurodegenerative disorders (23.6 %), and diabetes, both without (13.8 %) and with chronic complications (7.7 %). The following ECI components were more common in patients with COVID-19 pneumonia who died as a result of COVID-19 than in patients who recovered: congestive heart failure (p = 0.008), cardiac arrhythmias (p = 0.001), neurodegenerative disorders (p = 0.0003), diabetes mellitus (p = 0.004) including diabetes without chronic complications (p = 0.01), and obesity (p = 0.04). The ECI score in patients with a fatal outcome was 2.2 times higher (p < 0.05) than that in patients with COVID-19 pneumonia who recovered. The ECI >7 was predictive of the likelihood of COVID-19 death in patients with pneumonia (AUC = 0.656, p = 0.002).
Conclusions. The frequency of chronic comorbidities in patients with COVID-19 and pneumonia has been determined taking into account the ECI components. The prognostic significance of the ECI score >7 in assessing the risk of fatal outcome has been established.
References
Barek MA, Aziz MA, Islam MS. Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: A meta-analysis with 55 studies and 10014 cases. Heliyon. 2020;6(12):e05684. doi: https://doi.org/10.1016/j.heliyon.2020.e05684
Fang X, Li S, Yu H, Wang P, Zhang Y, Chen Z, et al. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. Aging. 2020;12(13):12493-503. doi: https://doi.org/10.18632/aging.103579
Little C, Alsen M, Barlow J, Naymagon L, Tremblay D, Genden E, et al. The Impact of Socioeconomic Status on the Clinical Outcomes of COVID-19; a Retrospective Cohort Study. J Community Health. 2021;46(4):794-802. doi: https://doi.org/10.1007/s10900-020-00944-3
Gao Y, Ding M, Dong X, Zhang J, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID‐19 patients: A review. Allergy. 2021;76(2):428-55. doi: https://doi.org/10.1111/all.14657
Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern Med. 2020;180(10):1345. doi: https://doi.org/10.1001/jamainternmed.2020.3539
COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med. 2021;47(1):60-73. doi: https://doi.org/10.1007/s00134-020-06294-x
Nandy K, Salunke A, Pathak SK, Pandey A, Doctor C, Puj K, et al. Coronavirus disease (COVID-19): A systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events. Diabetes Metab Syndr. 2020;14(5):1017-25. doi: https://doi.org/10.1016/j.dsx.2020.06.064
Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. PLoS One. 2020;15(8):e0238215. doi: https://doi.org/10.1371/journal.pone.0238215
Pavlou M, Ambler G, Seaman SR, Guttmann O, Elliott P, King M, et al. How to develop a more accurate risk prediction model when there are few events. BMJ. 2015;11:351:h3868. doi: https://doi.org/10.1136/bmj.h3868
Pule ML, Buckley E, Niyonsenga T, Roder D. The effects of comorbidity on colorectal cancer mortality in an Australian cancer population. Sci Rep. 2019;9(1):8580. doi: https://doi.org/10.1038/s41598-019-44969-8
Prommik P, Tootsi K, Saluse T, Strauss E, Kolk H, Märtson A. Simple Excel and ICD-10 based dataset calculator for the Charlson and Elixhauser comorbidity indices. BMC Med Res Methodol. 2022;22(1):4. doi: https://doi.org/10.1186/s12874-021-01492-7
Afolabi M, Johnston S, Tewari P, Danker W. Increasing Incremental Burden of Surgical Bleeding Associated with Multiple Comorbidities as Measured by the Elixhauser Comorbidity Index: A Retrospective Database Analysis. Med Devices (Auckl). 2023;16:237-49. doi: https://doi.org/10.2147/mder.s434779
Buhr RG, Jackson NJ, Kominski GF, Dubinett SM, Ong MK, Mangione CM. Comorbidity and thirty-day hospital readmission odds in chronic obstructive pulmonary disease: a comparison of the Charlson and Elixhauser comorbidity indices. BMC Health Serv Res. 2019;19(1):701. doi: https://doi.org/10.1186/s12913-019-4549-4
Azzalini L, Chabot-Blanchet M, Southern DA, Nozza A, Wilton SB, Graham MM, et al. A disease-specific comorbidity index for predicting mortality in patients admitted to hospital with a cardiac condition. CMAJ. 2019;191(11):E299-E307. doi: https://doi.org/10.1503/cmaj.181186
Tuty Kuswardhani RA, Henrina J, Pranata R, Anthonius Lim M, Lawrensia S, Suastika K. Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Metab Syndr. 2020;14(6):2103-9. doi: https://doi.org/10.1016/j.dsx.2020.10.022
Monterde D, Carot-Sans G, Cainzos-Achirica M, Abilleira S, Coca M, Vela E, et al. Performance of Three Measures of Comorbidity in Predicting Critical COVID-19: A Retrospective Analysis of 4607 Hospitalized Patients. Risk Manag Healthc Policy. 2021;14:4729-37. doi: https://doi.org/10.2147/rmhp.s326132
Zhou W, Qin X, Hu X, Lu Y, Pan J. Prognosis models for severe and critical COVID-19 based on the Charlson and Elixhauser comorbidity indices. Int J Med Sci. 2020;17(15):2257-63. doi: https://doi.org/10.7150/ijms.50007
Qeadan F, VanSant-Webb E, Tingey B, Rogers TN, Brooks E, Mensah NA, et al. Racial disparities in COVID-19 outcomes exist despite comparable Elixhauser comorbidity indices between Blacks, Hispanics, Native Americans, and Whites. Sci Rep. 2021;11(1):8738. doi: https://doi.org/10.1038/s41598-021-88308-2
Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity Measures for Use with Administrative Data. Med Care. 1998;36(1):8-27. doi: https://doi.org/10.1097/00005650-199801000-00004
van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A Modification of the Elixhauser Comorbidity Measures Into a Point System for Hospital Death Using Administrative Data. Med Care. 2009;47(6):626-33. doi: https://doi.org/10.1097/mlr.0b013e31819432e5
Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi: https://doi.org/10.1183/13993003.00547-2020
Fraccaro P, Kontopantelis E, Sperrin M, Peek N, Mallen C, Urban P, et al. Predicting mortality from change-over-time in the Charlson Comorbidity Index. Medicine. 2016;95(43):e4973. doi: https://doi.org/10.1097/md.0000000000004973
Gasparini A. Comorbidity: An R package for computing comorbidity scores. Journal of Open Source Software. 2018;3(23):648. doi: https://doi.org/10.21105/joss.00648
Thompson NR, Fan Y, Dalton JE, Jehi L, Rosenbaum BP, Vadera S, et al. A New Elixhauser-based Comorbidity Summary Measure to Predict In-Hospital Mortality. Med Care. 2015;53(4):374-9. doi: https://doi.org/10.1097/mlr.0000000000000326
Moore BJ, White S, Washington R, Coenen N, Elixhauser A. Identifying Increased Risk of Readmission and In-hospital Mortality Using Hospital Administrative Data. Med Care. 2017;55(7):698-705. doi: https://doi.org/10.1097/mlr.0000000000000735
Fritsche LG, Nam K, Du J, Kundu R, Salvatore M, Shi X, et al. Uncovering associations between pre-existing conditions and COVID-19 Severity: A polygenic risk score approach across three large biobanks. PLoS Genet. 2023;19(12):e1010907. doi: https://doi.org/10.1371/journal.pgen.1010907
Zhu D, Zhao R, Yuan H, Xie Y, Jiang Y, Xu K, et al. Host Genetic Factors, Comorbidities and the Risk of Severe COVID-19. J Epidemiol Glob Health. 2023 Jun;13(2):279-291. doi: https://doi.org/10.1007/s44197-023-00106-3
Nachtigall I, Kwast S, Hohenstein S, König S, Dang PL, Leiner J, et al. Retrospective, Observational Analysis on the Impact of SARS-CoV-2 Variant Omicron in Hospitalized Immunocompromised Patients in a German Hospital Network-The VISAGE Study. Vaccines (Basel). 2024;12(6):634. doi: https://doi.org/10.3390/vaccines12060634
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
